Gelderblom, Hans

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology

Sarcoma Diagnosis and TreatmentCardiac tumors and thrombi

Cited by 1,115

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 704

Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.

Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 617

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 551

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 513

Clinical pharmacokinetics of tyrosine kinase inhibitors

van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 503

Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 456

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 422

Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors

Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 362

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

de Vries, N. L., van de Haar, J., Veninga, V., Chalabi, M., Ijsselsteijn, M. E., van der Ploeg, M., van den Bulk, J., Ruano, D., van den Berg, J. G., Haanen, J. B., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 311

Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer

Dezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology

Pharmacogenetics and Drug MetabolismBreast Cancer Treatment Studies

Cited by 163

The tumour–stroma ratio in colon cancer: the biological role and its prognostic impact

van Pelt, G. W., Sandberg, T. P., Morreau, H., Gelderblom, H., van Krieken, J. H. J. M., Tollenaar, R. A. E. M., & Mesker, W. E. (2018) · Histopathology

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 155

Mitotane has a strong and a durable inducing effect on CYP3A4 activity

van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H. (2011) · European Journal of Endocrinology

Pharmacogenetics and Drug MetabolismAdrenal Hormones and Disorders

Cited by 118

Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination

Abdulrahman, R. M., Verloop, H., Hoftijzer, H., Verburg, E., Hovens, G. C., Corssmit, E. P., Reiners, C., Gelderblom, H., Pereira, A. M., Kapiteijn, E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and Treatment

Cited by 112

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research

Immune cells in cancerMonoclonal and Polyclonal Antibodies Research

Cited by 101

Osteosarcoma: Evolution of Treatment Paradigms

Jaffe, N., Puri, A., & Gelderblom, H. (2013) · Sarcoma

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 93

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review

Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 89

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., et al. (2009) · Cancer Chemotherapy and Pharmacology

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 47

Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).

McCabe, M., Kirton, L., Khan, M., Fenwick, N., Strauss, S. J., Valverde, C., Mata, C., Gaspar, N., Luksch, R., Longhi, A., et al. (2022) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

Cited by 46

Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial

Zunder, S., van der Wilk, P., Gelderblom, H., Dekker, T., Mancao, C., Kiialainen, A., Putter, H., Tollenaar, R., & Mesker, W. (2019) · Cellular Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 9